Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

As Roivant cements its deal for Dainippon to acquire five of its “vants” for $3 billion, the biotech revealed the identity of the deal’s fifth subsidiary, which will develop gene therapies